CHICAGO (TheStreet) -- AbbVie is spending $21 billion to buy half of a cancer drug. That's an extraordinary amount of money even though that cancer drug, Imbruvica, is fantastic and may become one the best-selling of all time. Pharmacyclics developed Imbruvica, which is approved to treat two different types of blood cancer.